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A B S T R A C T   
In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA- 
REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the out-
comes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in 
patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among 
double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For 
double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that 
the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.   
1. Introduction 
Diffuse Large B-cell lymphomas (DLBCLs) are by far the most com-
mon non-Hodgkin’s lymphomas (NHLs) [1]. DLBCL is a heterogeneous 
[2], highly aggressive [3], clonal neoplasm of large B-lymphoid cells 
originating from germinal centers. The disease is characterized by 
massive lymphadenopathy and constitutional symptoms [4] and con-
stitutes 40% of all NHLs globally, with a higher prevalence in developing 
countries [5]. Indeed, a study from Pakistan found 76.4% of all NHLs to 
be diagnosed as DLBCLs [6]. 
In keeping with this, the treatment of DLBCLs is under extensive 
research. Half a century ago, the standard of treatment regimen was a 
combination of chemotherapy with cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) [7]. This regimen resulted in 
response rates of 45–55%, with 30–40% of patients achieving cure [7, 
8]. Despite the advent of newer regimens, CHOP remained the mainstay 
of therapy for decades because of superior cure rates and lesser toxicity 
[8]. Recently, a new regimen, with the addition of rituximab to the 
previous combination chemotherapy (R-CHOP) showed promise with 
better cure rates (of 50–60%) [4] without increased toxicity [9]. Despite 
the success of R-CHOP, there are important shortcomings to this com-
bination chemotherapy. Liu et al. reported that, of the 40% of patients 
who have refractory disease or those who relapse, most patients will not 
respond to this chemotherapy [4]. Considering this, newer regimens are 
being investigated to improve survival. One such combination is 
dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophos-
phamide, and doxorubicin (DA-REPOCH) [7]. However, studies 
comparing the effectiveness of R-CHOP with that of DA-REPOCH have 
been inconclusive. Bartlett et al. found no difference between the two 
treatments [10]. Yet, Knouse et al. reported that while there was no 
improvement in survival between the two treatments, fewer patients in 
the DA-REPOCH arm relapsed or progressed after treatment [7], sug-
gesting that the benefits of this new treatment must be re-evaluated. 
With results of prior studies inconclusive, it is necessary to assess the 
effectiveness of R-DA-EPOCH combination therapy to assess any ad-
vantages of this treatment. Thus, this study aims to compare the survival 
rates of the DA-REPOCH regimen with the R-CHOP chemotherapy 
regimen. 
; COO, Cell of Origin; DLBCL, Diffuse large B-cell Lymphoma; OS, Overall Survival; PFS, Progression Free Survival; R-CHOP, rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone; R-DA-EPOCH, rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; WHO, 
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2. Methods 
A retrospective study design was used to investigate the treatment 
outcomes of patients previously diagnosed with the either DE or TE 
subtype of DLBCL compared with non-expressor DLBCL. A sample of 113 
patients who presented to the tertiary care hospital at Karachi, Pakistan 
was selected. All consenting patients aged 18 and above, with a diag-
nosis of DE or TE subtype of DLBCL as per World Health Organization 
(WHO) classification, who were treated between January 1, 2019, to 
December 31, 2020, with either DA-REPOCH or R-CHOP, were included 
in the study. Patients with a history of prior treatment for aggressive or 
indolent lymphoma were not included. All toxicities that were reported 
were graded using the common terminology criteria for adverse events, 
version 5.0 [11]. Participants’ demographic characteristics, such as age, 
sex, and co-morbidities; disease characteristics, such as disease stage, 
cell of origin, expressors, and International Prognostic Index (IPI) scores; 
and treatment variables, such as the type of treatment given, and the 
number of chemotherapy cycles were recorded in the study. The data 
were analyzed using STATA version 16.0. All independent and outcome 
variables were analyzed descriptively. Normally distributed continuous 
variables were represented as means and standard deviations while 
categorical variables were presented as frequency counts and percent-
ages. Progression-free survival (PFS) and overall survival (OS) were 
calculated in months using the Kaplan-Meier survival function. In 
addition, the log-rank test was conducted to compare survival distri-
butions. Cox proportional hazard regression model was used to analyze 
the results [12]. Univariate analysis was conducted to assess the sig-
nificance of variables. Then the inter-variable multicollinearity was also 
assessed. All variables with a significance of ≤0.25 were admissible in 
the multivariable model and significant variables without multi-
collinearity were analyzed at p-value ≤0.05 on multivariable analysis. 
3. Results 
A total of 113 patients were treated for DLBCL from January 1, 2019, 
to December 31, 2020. The total follow-up was of two years duration (24 
months). Out of the 113 patients, 44 (39%) were non-expressors and 69 
(61%) had double/triple expressor lymphomas. R-CHOP was given as 
standard therapy to 44 (39%) of the DLBCL patients. Of the 69 (61%) 
patients with double/triple expressor lymphoma, R-DA-EPOCH was 
administered to 18 (26.1%), R-CHOP was administered to 38 (55.1%), 
and 13 (18.8%) received other treatment regimens i.e., R-Benda and R- 
CVP. 
4. Baseline demographic and clinical characteristics of 
participants 
The baseline characteristics of the patients with non-expressor (NE) 
and double/triple expressor lymphoma diagnosed basis of IHC receiving 
different treatment regimens (R-DA-EPOCH, R-CHOP, and Others) are 
displayed in Table 1. The mean (±SD) age of non-expressor DLBCL pa-
tients was 52.5 (±15.5) years, while the mean age of participants with 
double/triple expressor lymphoma receiving R-DA-EPOCH was 50 
(±14.7) years, R-CHOP was 56.6 (±11.1) years, and those receiving 
other treatments was 63.8 (±9.0) years. Out of the 44 non-expressor 
DLBCL patients, 30 (68.2%) were male and 14 (31.8%) were female. 
Among the 69 patients with double/triple expressor lymphoma, there 
were 9 (13%) males and 9 (13%) females in the R-DA-EPOCH arm, and 
22 (31.9%) males and 16 (23.3%) females in the R-CHOP arm, and 9 
(13%) males and 4 (5.8%) females in the other treatment arm. DLBCL 
subtypes were described based on the cell of origin. Among the 44 non- 
expressor DLBCL cases, 28 (63.6%) cases had the germinal center B-cell 
(GCB) subtype, while among those with double/triple expressor lym-
phoma, 36 (52.2%) cases had the subtype with germinal center B-cells 
(GCB). They latter received either R-DA-EPOCH, R-CHOP, or other 
treatment regimens. Most patients had stage IV disease by Lugano 
staging system, with 31 (70.5%) patients from the non-expressor DLBCL 
group and 55 (79.7%) patients from the double/triple expressor lym-
phoma group. The two main comorbidities were hypertension and dia-
betes mellitus, found in 15.9% of NE DLBCL patients and 63.8% of 
double/triple expressor lymphoma patients. The median Eastern Coop-
erative Oncology Group (ECOG) score in patients with both NE DLBCL 
and double/tripe expressor lymphoma was [1]. The median IPI score for 
patients with NE DLBCL was 3, while the group with double/triple 
expressor lymphoma receiving DA-EPOCH had a score of 5, and the 
group with double/triple expressor lymphoma receiving R-CHOP and 
other treatment regimens had a score of 6. The median central nervous 
system IPI (CNS IPI) score was 3 for patients with NE DLBCL and 4 for 
patients with double/triple expressor lymphoma receiving any treat-
ment. Among NE DLBCL patients, 23 (52.3%) received 6 cycles of 
R-CHOP, while out of the 69 patients with double/triple expressor 
lymphoma, 13 (18.8) received 6 cycles of R-DA-EPOCH, 25 (36.2) 
received 6 cycles of R-CHOP, and 10 (14.5%) received 6 cycles of other 
treatment regimens. 
The survival rate in NE DLBCL patients receiving R-CHOP as the 
standard treatment was 81.8%, while the survival rate was 82.8% 
among double/triple expressor lymphoma patients receiving R-DA- 
EPOCH, and 83.3% among double/triple expressor lymphoma patients 
receiving R-CHOP. For those who received treatment other than these 
two treatment regimens, i.e., R-Benda and R-CVP, the survival rate was 
62.5% (Table 2). 
Table 1 
Baseline clinical characteristics of patients with diffuse large B-cell lymphoma.  
Variables Expressors n = 113 (n%) 
Non-Expressor 
(n = 44) 














14 (31.8)  
9 (13.0) 
9 (13.0)  
22 (31.9) 







28 (63.6)  
8 (11.6) 
10 (14.5)  
19 (27.5) 














































ECOG (median) 1 1 1 1 
IPI Score (median) 3 5 6 6 
CNS IPI Score 
(median) 





27 (61.4)  
3 (4.3) 
15 (21.7)  
4 (5.8) 




No. of Chemotherapy 
Cycles 
≤5   21 (47.7)   5 (7.2)   13 (18.8)   3 (4.3) 
6 23 (52.3) 13 (18.8) 25 (36.2) 10 
(14.5) 
Abbreviations: COO subtype, cell of origin subtype; ECOG PS, eastern coop-
erative oncology group performance status; GCB, germinal center; IPI, interna-
tional prognostic index; LDH, lactate dehydrogenase; R-CHOP, rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH, 
rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, 
and doxorubicin. 
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5. Progression-free survival (PFS) and overall survival (OS) 
At 2 years, the median PFS for the entire cohort was 19.6 months 
(range 2.3- 21.6 months). Median 2-year OS (n = 85) was 16.8 months 
(3.3–24 months) while OS till the last follow-up was 22.5 months 
(1.5–24 months). Among the NE DLBCL patients, the median 
progression-free survival was 10.3 months while the overall survival 
was 13.6 months. For double/triple expressor lymphoma patients, in 
those receiving R-DA-EPOCH, the PFS was 10.5 months and OS was 13.8 
months, in those receiving R-CHOP, the PFS was 10.6 months and OS 
was 14.2 months and in those receiving other treatment regimens, the 
PFS was 6.6 months and OS 10.6 months (Table 3, Fig. 1, 2& 3). 
6. Description of toxicity by treatment 
A description of the toxicity by grade with each treatment regimen is 
displayed in Table 4. Adverse events are divided into two broad cate-
gories: hematologic and non-hematologic. Most patients had hemato-
logic adverse events i.e., neutropenia, pancytopenia, or anemia, and 
most had a severity of grade 3 or 4. When excluding hematologic events, 
gastrointestinal events were the most common adverse events, with 
severity of grade 3 or 4. 
7. Univariate and multivariable analysis 
The Univariate and Multivariable regression model was applied, 
assessing the association between treatment regimen received by the 
patient and the outcome, which is given in Table 5. Both univariate and 
multivariable analysis showed that the treatment regimen, disease 
expressors, and toxicity are significant prognostic factors for overall 
survival in DLBCL. The hazard ratio for survival in patients who received 
R-CHOP was 1.9 times (95% CI 1.1–6.8) compared to those who 
received R-DA-EPOCH or other treatments. The hazard ratio of survival 
in patients who received other treatments was 4.3 times (95% CI 
1.2–6.5) compared to those who received R-DA-EPOCH or R-CHOP. 
Additionally, the hazard ratio of survival in NE DLBCL patients was 2.6 
times (95% CI 1.1–6.4) compared to double/triple expressor lymphoma. 
Moreover, the hazard ratio of survival in patients who have pancyto-
penia was 3.1 times (95% CI 1.6–5.5) compared to neutropenia and 
other adverse events, while the hazard ratio of survival in patients who 
had other adverse events was 5.6 times (95% CI 1.2–7.7) compared to 
neutropenia and pancytopenia. 
8. Discussion 
The treatment of double/triple expressor DLBCL remains a 
Table 2 
The overall survival rate in patients receiving different chemotherapy regimens 
for DLBCL after a two-year follow-up.  
Survival rate Expressors n = 113 (Number of patients%) 
Non-Expressor(n = 44) Double/Triple expressor (n = 69) 
R-CHOP R-DA-EPOCH R-CHOP Others 
% 81.8 82.8 83.3 62.5  
Table 3 
Progression-free survival and overall survival at 2 years of the follow-up.  
Survival rate Median PFS and OS (in months) 
Non-Expressor(n 
= 44) 




Progression Free Survival 
(months) 
10.3 10.5 10.6 6.6 
Overall Survival (months) 13.6 13.8 14.2 10.6  
Fig. 1. Kaplan Meir plot for overall survival (in months) for NE DCBCL and 
double/triple expressor lymphoma combined. 
Fig. 2. Kaplan Meir plot for overall survival (in months) in NE and double/ 
triple expressor lymphoma. 
Fig. 3. Kaplan Meir plot for overall survival (in months) in double/triple 
expressor lymphoma receiving each of the three treatment regimens. 
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challenge. Double/triple expressor lymphomas contain both MYC and 
BCL-2 and/or BCL-6 expression without translocation. There is a poor 
prognosis in patients with expression of both MYC and BCL2 [13]. 
Hence, studies have shown that double/triple expressor lymphomas 
have an invasive, aggressive clinical course and respond poorly to 
standard R-CHOP therapy, with an average OS of 5 months to 2 years 
[14–16]. In fact, 40% of patients relapse, and mortality rates are high, 
even after receiving R-CHOP [8]. Despite this poor course, few treat-
ments have proven more effective than R-CHOP at improving survival. 
R-DA-EPOCH is a newer regimen that holds promise for the treat-
ment of double/triple expressor lymphoma [17]. This study shows that 
the survival rate of double/triple expressor lymphoma patients receiving 
R-DA-EPOCH is more or less similar to the survival rate of double/triple 
expressor lymphoma patients receiving R-CHOP (82.8% vs 83.3%). A 
possible reason for this may also be the dominant GCB subtype, with has 
present in roughly half of all types, as is also reported in literature [9, 
10]. Petrich et al. reported that R-DA-EPOCH showed significant ad-
vantages over RCHOP for PFS and OS [17], suggesting that R-DA-E-
POCH may demonstrate therapeutic advantages [18]. However, as some 
of these studies may be limited by small sample sizes. More recently, 
Dodero et al. found similar outcomes for both groups [19]. The authors 
also found that treatment in younger patients was more efficacious 
because they received a higher dose [19]. Magnusson et al. also reported 
no difference between the R-CHOP and R-EPOCH regimens [20]. The 
study further looked at the risks of poor outcomes and found LDH to be 
associated with poor prognosis. We studied the association of LDH via 
the IPI and found no association. While evidence may be varied, it seems 
to weight towards no difference between the two regimens. 
As the R-DA-EPOCH regimen is administered as a continuous intra-
venous infusion, the incidence of adverse reactions is expected to be 
high [19]. However, our study also found fewer adverse events in the 
R-DA-EPOCH arm compared to the R-CHOP arm (Table 4). Hemato-
logical adverse events were the most common, mostly constituting 
pancytopenia, followed by neutropenia. Of those receiving R-DA-E-
POCH, 9.7% of patients developed pancytopenia, compared to 29.2% of 
patients receiving R-CHOP. These adverse events were reversed shortly 
after symptomatic treatment. None of the patients developed 
chemotherapy-related deaths or secondary malignancy. Ma et al. re-
ported no significant difference in adverse effects in patients with 
R-DA-EPOCH compared to R-CHOP [18]. However, Knouse et al. has 
also reported fewer adverse effects with R-DA-EPOCH [10]. The authors 
suggest this may be due to the different age ranges of patients treated 
with either regimen, as more patients in the R-CHOP arm were aged at 
least 70 years. However, the difference in age ranges in patients treated 
with R-DA-EPOCH and R-CHOP in our study was minimal (56.6 ± 11.1 
vs 50 ± 14.7). However, there were some other differences in the 
number of patients with a higher stage of disease, comorbidities, and 
prognostic scores. Hence, we cannot conclude whether R-DA-EPOCH 
has fewer adverse events than R-CHOP. Further studies, with matched 
cohorts, may be required to study this. 
There are some limitations to our study. It is a single-center study 
and has a small sample size of 113 patients due to the rare nature of the 
disease. It is also for this reason that we could not balance the baseline 
demographic and disease characteristics of patients who received each 
treatment. Despite these limitations, this is a prospective study design 
that has reported data on the PFS, OS, and adverse effects of treatments 
for high-risk DLBCL. It is also the first study of its kind from the local 
population. 
This study shows similar efficacy of R-DA-EPOCH as compared to R- 
CHOP for the treatment of double/triple expressor lymphoma. We have 
also demonstrated fewer adverse effects with R-DA-EPOCH compared 
with R-CHOP, suggesting its value as a possible first-line treatment in 
Table 4 
Description of the toxicity with grade by treatment received (R-DA-EPOCH, R- 
CHOP, and Others).  
Adverse Event Grade 
1/2, n 
(%) 
















































































































Univariate and Multivariable Survival Analysis Reporting Crude and Adjusted 
Hazard Ratio with 95% Confidence Interval for overall survival in DLBCL.  
Variables CHR (95% 
CI) 











0.03  1 
1.9 (1.1–6.8) 
4.3 (1.2–6.5)  
<
0.001 
Age (years) 1.01 
(1.0–1.4) 





1.5 (0.7–3.1)  





1.2 (0.6–2.5)  





2.5 (1.1–5.9)  
0.08  1 




















1.5 (0.5–4.2)  
0.74  -  - 
ECOG 1.3 (0.8–2.3) 0.29 – – 
IPI Score 1.2 (0.9–1.6) 0.13 – – 





1.9 (0.6–5.4)  
0.21  -  - 





1.4 (0.7–3.0)  









0.08  1 
3.1 (1.6–5.5) 
5.6 (1.2–7.7)  
<
0.001 
Abbreviations: COO subtype, cell of origin subtype; ECOG PS, eastern coop-
erative oncology group performance status; GCB, germinal center; IPI, interna-
tional prognostic index; LDH, lactate dehydrogenase; R-CHOP, rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone; R-DA-EPOCH, 
rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, 
and doxorubicin; CHR: Crude Hazard Ratio; AHR: Adjusted Hazard Ratio. 
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high-risk DLBCL. In the future, multicentered studies, with larger sample 
sizes, equal distribution of treatments, and matching, are required to 
better compare the efficacy and safety of R-DA-EPOCH with that of R- 
CHOP in the treatment of double/triple expressor lymphoma to improve 
progression-free survival and overall survival in this aggressive disease. 
9. Conclusion 
In conclusion, the findings of our study demonstrated that the sur-
vival rate in both R-CHOP and R-DA-EPOCH is mostly similar. A 
multicenter, large-scale study with equal distribution of treatment reg-
imens is needed for comparison to establish the usefulness of the R- 
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